Recombinant Human Prokineticin receptor 1 (PROKR1)

What expression systems are optimal for producing functional recombinant human PROKR1 for ligand-binding assays?

Recombinant PROKR1 requires proper post-translational modifications for ligand-binding functionality. Mammalian systems (e.g., HEK293, CHO-K1) are preferred over bacterial systems due to their ability to support GPCR folding and glycosylation . For kinetic binding assays, transient transfection with a C-terminal tag (e.g., HA or FLAG) enables immunoprecipitation validation. A 2023 study demonstrated that HEK293 cells expressing PROKR1 showed robust cAMP response element-binding protein (CREB) phosphorylation upon ligand activation, confirming functional coupling to Gs proteins .

Key Parameters for Expression Optimization:

How can researchers distinguish PROKR1-specific signaling from cross-talk with PROKR2 in vitro?

PROKR1 and PROKR2 share 85% sequence homology but exhibit ligand selectivity. Use pharmacological tools:

• PROKR1-specific agonist: PK1-C (EC₅₀ = 1.2 nM for PROKR1 vs. >100 nM for PROKR2) .

• PROKR2-specific antagonist: PC-7 (IC₅₀ = 5 nM for PROKR2; no effect on PROKR1) .
  Combine siRNA knockdown (e.g., siRNA-PROKR1 reduces oxidative fiber specification in myotubes by 60%, while siRNA-PROKR2 has no effect ).

What are validated methods to quantify PROKR1-mediated intracellular signaling in muscle cells?

PROKR1 activates Gs-coupled pathways, increasing cAMP and phosphorylated CREB (pCREB). Methodological steps:

• Stimulation: Treat human myotubes with 10 nM PROK1 for 15 min .

• Detection:

  • pCREB: Western blot (anti-pCREB Ser133; 1:1,000 dilution).

  • NR4A2 induction: qPCR (2^-ΔΔCt method; primers for NR4A2 vs. GAPDH) .

• Functional readouts: Mitochondrial respiration (Seahorse XF Analyzer) shows 30% increase in OCR in PROKR1-activated myotubes .

How does tissue-specific PROKR1 signaling explain contradictory roles in neuronal survival versus muscle metabolism?

PROKR1 exhibits context-dependent signaling:

• Muscle: Gs-cAMP-CREB-NR4A2 axis upregulates oxidative fiber genes (e.g., PGC-1α, COX4), enhancing mitochondrial biogenesis .

• Neurons: PROKR1 activation reduces proliferation via p38 MAPK inhibition (50% decrease in BrdU incorporation at 1 nM PROK1) .

Tissue-Specific Signaling Outcomes:

Resolution of Data Contradictions: Tissue-specific G protein coupling (Gs in muscle vs. Gq in neurons) explains divergent phenotypes. Use conditional knockout models (e.g., Prokr1^flox/flox crossed with tissue-specific Cre lines) to isolate pathways .

What experimental strategies resolve discrepancies in PROKR1’s role in angiogenesis across cardiac versus reproductive tissues?

PROKR1 promotes angiogenesis in cardiac endothelial cells but not in luteal endothelial cells:

• Cardiac: PROKR1 overexpression increases capillary tube formation by 2.5-fold via Akt phosphorylation, independent of VEGF .

• Corpus Luteum: PROKR1 stabilizes existing vessels via Angiopoietin-1 secretion but does not induce new sprouting .

Methodological Recommendations:

• 3D Matrigel Assay: Use tissue-specific endothelial cells (e.g., cardiac vs. ovarian).

• Pathway Inhibition: Co-treat with Akt inhibitor MK-2206 (10 μM) to confirm PROKR1-Akt dependency in cardiac angiogenesis .

How can researchers model PROKR1’s dual role in cell survival (cardiac) versus apoptosis (neuronal) in vitro?

Adopt co-culture systems to isolate microenvironmental factors:

• Cardiomyocyte Survival: H9c2 cells + PROKR1 agonist (10 nM PK1-C) → 40% reduction in H₂O₂-induced apoptosis via Akt-Bcl2 axis .

• Neuronal Apoptosis: SH-SY5Y cells + PROKR1 siRNA → 25% increase in caspase-3 activity under serum-free conditions .

Key Controls:

• Include PROKR1-negative cells (CRISPR knockout) to confirm receptor specificity.

• Measure cross-talk with PROKR2 using selective antagonists .

What computational models predict PROKR1 ligand-binding dynamics for novel agonist design?

Molecular dynamics (MD) simulations of PROKR1 extracellular loops (ECL2-3) identify critical residues for ligand docking :

• Residue D115: Hydrogen bonding with PROK1’s C-terminal amide group (ΔG = -9.2 kcal/mol).

• Residue Y220: Hydrophobic interaction with PROK1’s β-hairpin .

In Silico Workflow:

• Homology Modeling: Use bovine rhodopsin (PDB:1U19) as a template .

• Docking: AutoDock Vina with PROK1 (PDB:2KS9).

• Validation: Compare predicted ΔG with experimental IC₅₀ from radioligand displacement assays .

Methodological Best Practices

• Data Reproducibility: Validate PROKR1 antibodies using knockout lysates (e.g., Prokr1^-/- mice show no bands at 45 kDa) .

• Contradiction Analysis: Use pathway enrichment tools (Ingenuity IPA) to identify tissue-specific signaling nodes .

• Ethical Reporting: Disclose PROKR1’s pleiotropic roles in grant applications to avoid oversimplification of therapeutic potential .